Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 3 23Phase 1 21Phase 1/2 17Phase 4 6Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Neoplasm Metastasis 1

Interventions

Letrozole 23Docetaxel 17Cyclophosphamide 13Zoledronic Acid 12Trastuzumab 12Anastrozole 12exemestane 11Tamoxifen 11Paclitaxel 11Capecitabine 10Fulvestrant 8Epirubicin 8pegfilgrastim 7Saline Solution 7Bupivacaine 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Sodium Chloride 6Filgrastim 6Carboplatin 6pegylated granulocyte colony-stimulating factor 5palbociclib 5Ropivacaine 5Dexmedetomidine 5Bevacizumab 5ribociclib 4eribulin 4Vinorelbine 4Tranexamic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × abemaciclib × Breast × Clear all
NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

NCT06169371 2026-01-14

BRE-09

University of Illinois at Chicago

Phase 4 Recruiting
50 enrolled
Breast

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

University of Ulm

Phase 4 Recruiting
300 enrolled
Breast

Breast Neoplasms

NCT04707196 2023-11-24

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Eli Lilly and Company

Phase 4 Completed
200 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Eli Lilly and Company

Phase 4 Terminated
4 enrolled 9 charts
Breast

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Eli Lilly and Company

Phase 4 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡